-

Agilent Makes Strategic Updates to Organizational Structure

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced it has moved the company’s Cell Analysis Division into its Diagnostics and Genomics Group (DGG) as part of a strategy to further strengthen growth opportunities for both organizations.

“We believe having the cell analysis team as part of DGG is a natural fit given the markets they serve and the clear linkages to our genomics and diagnostics customers,” said Mike McMullen, Agilent president and CEO.

Share

“We believe having the cell analysis team as part of DGG is a natural fit given the markets they serve and the clear linkages to our genomics and diagnostics customers,” said Mike McMullen, Agilent president and CEO. “This is an exciting opportunity to bring our unique collection of cell and molecular-based solutions together in ways that better align with how our customers are working. This will in turn expand workflow coverage and drive accelerated growth.”

Formerly part of Agilent’s Life Sciences and Applied Markets Group (LSAG), the company’s cell analysis work has been an important growth driver for the company. Created primarily through the acquisitions of BioTek Instruments, ACEA Biosciences, and Seahorse Bioscience over the last eight years, the cell analysis organization has developed differentiated, industry leading products and represents a key example of the success of Agilent’s “build and buy” growth strategy.

Agilent will report under this new structure beginning with the company’s first quarter fiscal 2024 results and will recast historical segment information to conform to the new reporting structure in financial statements and accompanying notes beginning with the Form 10-Q filing. To assist with the comparability of information, in January 2024, Agilent will provide a recast of the three prior years by quarter in accordance with the new reporting segments in a Form 8-K.

About Agilent Technologies

Agilent Technologies Inc. (NYSE: A) is a global leader in analytical and clinical laboratory technologies, delivering insights and innovation that help our customers bring great science to life. Agilent’s full range of solutions includes instruments, software, services, and expertise that provide trusted answers to our customers' most challenging questions. The company generated revenue of $6.83 billion in fiscal 2023 and employs approximately 18,000 people worldwide. Information about Agilent is available at www.agilent.com. To receive the latest Agilent news, subscribe to the Agilent Newsroom. Follow Agilent on LinkedIn and Facebook.

Contacts

Investor Contact:
Parmeet Ahuja
+1 408-345-8948
parmeet_ahuja@agilent.com

Media Contact:
Tom Beermann
+1 408 386 5892
tom.beermann@agilent.com

Agilent Technologies Inc.

NYSE:A
Details
Headquarters: Santa Clara, California, USA
CEO: Padraig McDonnell
Employees: 18000
Organization: PUB

Release Versions

Contacts

Investor Contact:
Parmeet Ahuja
+1 408-345-8948
parmeet_ahuja@agilent.com

Media Contact:
Tom Beermann
+1 408 386 5892
tom.beermann@agilent.com

Social Media Profiles
More News From Agilent Technologies Inc.

Agilent, OpenAI, BCG Collaborate to Accelerate Customer-Focused, AI-Driven Scientific Innovation

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced a collaboration with OpenAI and Boston Consulting Group (BCG) to accelerate the deployment of artificial intelligence (AI) across the company’s products, operations, and customer workflows. “AI is a top priority, and this partnership reflects both our ambition and our execution commitment — to build the enduring capability, operating model, and capacity required to consistently deliver AI‑driven innovation...

Agilent Receives FDA Approval for Expanded Use of PD-L1 IHC 22C3 pharmDx on Dako Omnis in Esophageal Squamous Cell Carcinoma, Triple-Negative Breast Cancer, Cervical Cancer, and Gastric or Gastroesophageal Junction Adenocarcinoma

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced that the U.S. Food and Drug Administration (FDA) has approved the expanded use of PD-L1 IHC 22C3 pharmDx, Code GE006, for use on the Dako Omnis platform to aid in identifying patients in the United States with esophageal squamous cell carcinoma (ESCC)3, triple-negative breast cancer (TNBC)4, cervical cancer5, and gastric or gastroesophageal junction (GEJ) adenocarcinoma6, who may be eligible for treatment...

Agilent Introduces OpenLab Sync to Support Guided, Digital Execution in the Laboratory

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced the introduction of OpenLab Sync, a new Lab Execution System (LES) that enables laboratories to digitally connect scientific workflows from method design through execution at the bench. OpenLab Sync extends Agilent’s OpenLab laboratory informatics portfolio beyond traditional data and sample management, enabling guided, standardized, and traceable execution of laboratory work in regulated environments. As...
Back to Newsroom